Stocklytics Platform
Asset logo for symbol ZNTL
Zentalis Pharmaceuticals
ZNTL37
$1.35arrow_drop_down0.07%-$0.00
Penny Stock
Asset logo for symbol ZNTL
ZNTL37

$1.35

arrow_drop_down0.07%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Zentalis Pharmaceuticals (ZNTL) Stocklytics Forecast

Zentalis Pharmaceuticals Inc (ZNTL) is an innovative biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company's mission is to discover, develop, and commercialize novel small molecule treatments that can make a meaningful difference in the lives of cancer patients. With a strong pipeline of potential therapies, Zentalis Pharmaceuticals is well-positioned for future growth.
In terms of stock price prediction, it is always important to note that the stock market is inherently unpredictable and can be influenced by various factors. However, analysts have expressed positive sentiments regarding Zentalis Pharmaceuticals Inc's stock. Many analysts have provided a price target for ZNTL stock, indicating where they believe the stock price may reach in the future. These price targets are based on extensive research and analysis of the company's financials, pipeline, and growth potential.
add Zentalis Pharmaceuticals  to watchlist

Keep an eye on Zentalis Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Zentalis Pharmaceuticals (ZNTL) stock?

Analysts have set a target price of $42.78 for Zentalis Pharmaceuticals (ZNTL), based on forecasts from 23 analysts. The predicted price range extends from a high of $70 to a low of $12. This represents a potential increase of up to 5.05K% and a decrease of 783% from the current price of $1.36. These forecasts are as of 2022 Nov 10.
help

What are the analyst ratings for Zentalis Pharmaceuticals (ZNTL) stock?

The analyst ratings for Zentalis Pharmaceuticals (ZNTL) are distributed as follows: 5 analysts recommend buying, 6 have a neutral stance, and 0 suggest selling. The prevailing sentiment among the total of 11 analysts leans towards a neutral rating. These ratings indicate the general sentiment among the analysts covering Zentalis Pharmaceuticals .
help

What is the AI price prediction for Zentalis Pharmaceuticals (ZNTL) stock?

At present, there is no AI or machine-learning-based price prediction available for Zentalis Pharmaceuticals (ZNTL) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level